Uterine Papillary Serous Cancer (UPSC) Trial

Inclusion Criteria: * Patients with histologically confirmed UPSC at surgical stage 1b to 4 disease. The serous-papillary component of the specimen must be at least 30 percent. Patients with surgical stage 1a disease should not be enrolled. * Females aged \>= 18 years old. * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. * Patients may not have received any prior chemotherapy regimens for UPSC. * Patients must have adequate bone marrow, renal, hepatic and neurologic function. * Patients must be informed of the investigational nature of the study and sign an informed consent form. * Patients with previous malignancy are eligible only if the patient has been disease-free for \>= 5 years. Exclusion Criteria: * Patients with pre-existing \>= grade 2 neurotoxicity. * Patients with uncontrolled hypertension, (systolic blood pressure \>180 mm Hg or diastolic blood pressure \>100 mm Hg) or uncontrolled cardiac arrhythmia or diabetes mellitus * Patients with a history of other malignancy within the last 5 years that could affect the diagnosis or assessment of UPSC. * Patients who have a history of serious cardiac disease that is not adequately controlled are not allowed. Patients with documented myocardial infarction within 6 months preceding study entry; congestive heart failure; unstable angina; a clinically significant pericardial effusion; or arrhythmias are also ineligible. * Patients with an active serious infection or other serious underlying medical condition that would otherwise impair their ability to receive protocol treatment. * Serious medical or psychiatric illnesses that would prevent informed consent. Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent. * Patients with prior significant allergic reactions to drugs containing cremophor, such as cyclosporine, or vitamin K are not eligible. A significant reaction may be defined as, but is not limited to, the description of grade \>= 3 allergic reactions using the Common Toxicity Criteria (CTC). Patients with known hypersensitivity to paclitaxel, carboplatin or Cremophor EL. * Patients who have received prior whole pelvis radiotherapy. * Patients with uncontrolled pelvic inflammatory disease that would contraindicate pelvic radiotherapy. * Patients who are pregnant or breast-feeding. * Patients receiving other investigational therapy.